Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis.

Jing LiHeyue DuYang WangBert AertgeertsGordon GuyattQiukui HaoYanjiao ShenLing LiNa SuNicolas DelvauxGeertruida BekkeringSafi U KhanIrbaz B RiazPer Olav VandvikBaihai SuHaoming TianSheyu Li

Published in: Heart (British Cardiac Society) (2022)

PCSK9 inhibitors slightly increase the risk of severe injection-site reaction but not cataracts, gastrointestinal haemorrhage, neurocognitive events, new-onset diabetes or severe myalgia or muscular pain.

Keyphrases

low density lipoprotein
early onset
type diabetes
chronic pain
cardiovascular disease
neuropathic pain
ultrasound guided
spinal cord
resistance training
metabolic syndrome
adipose tissue
insulin resistance
body composition
high intensity